Nombre de droits de vote au 30 avril 2024
May 02, 2024 11:45 ET
|
NICOX SA
Nicox SA Société anonyme au capital de 50 299 694 euros Siège social : Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois, 06410 BiotR.C.S. ANTIBES 403.942.642 Le 02 mai 2024, ...
Number of voting rights as of April 30, 2024
May 02, 2024 11:45 ET
|
NICOX SA
Nicox SA Société anonyme with a registered capital of € 50,299,694 Head Office: Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois – 06410 BiotR.C.S. ANTIBES 403.942.642 On May 2nd,...
Cluster Headache Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Lundbeck Seattle Biopharmaceuticals, Clexio Biosciences
April 29, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 29, 2024 (GLOBE NEWSWIRE) -- Cluster Headache Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Lundbeck Seattle...
Nicox : Deuxième convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 6 mai 2024 et désignation d’un mandataire ad hoc
April 24, 2024 01:30 ET
|
NICOX SA
Communiqué de presseNicox : Deuxième convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 6 mai 2024 et désignation d’un mandataire ad hoc24 avril 2024 – diffusion à 07h30Sophia...
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
April 24, 2024 01:30 ET
|
NICOX SA
Press Release Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agentApril 24, 2024 – release at 07:30 CET Sophia Antipolis,...
Nicox : Point financier sur le premier trimestre 2024 et résultats financiers de l’année 2023
April 22, 2024 01:30 ET
|
NICOX SA
Communiqué de presseNicox : Point financier sur le premier trimestre 2024 et résultats financiers de l’année 2023 Chiffre d’affaires du Groupe de €4,4 millions (net1 de €3,9 millions) pour le premier...
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
April 22, 2024 01:30 ET
|
NICOX SA
Press Release Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million (net revenue1 €3.9 million) for first quarter 2024Nicox Group cash of...
Treatment-Resistant Hypertension Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Idorsia, Janssen Biotech, Quantum Genomics, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma
April 09, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- Treatment-Resistant Hypertension Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Idorsia, Janssen...
Nicox : Assemblée Générale Ordinaire et Extraordinaire 2024
April 09, 2024 11:30 ET
|
NICOX
Communiqué de presseNicox : Assemblée Générale Ordinaire et Extraordinaire 20249 avril 2024 – diffusion à 17h30 Sophia Antipolis, FranceNicox SA (Euronext Paris : FR0013018124, ALCOX, éligible...
Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting
April 09, 2024 11:30 ET
|
NICOX
Press Release Nicox: 2024 Ordinary and Extraordinary Shareholder MeetingApril 9, 2024 – release at 17:30 CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, ALCOX), an international...